Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1397692 | 0.95 | NLRP3 (0.31) | C5AR1NLRP3CHRNA7NR3C1FFAR4 | |
| SCHEMBL1397661 | 0.87 | SLC34A2 (0.33) | — | |
| SCHEMBL1397368 | 0.86 | SIGMAR1 (0.31) | — | |
| SCHEMBL1397372 | 0.82 | CNR1 (0.33) | — | |
| SCHEMBL1397763 | 0.81 | C5AR1 (0.32) | C5AR1FFAR4 | |
| SCHEMBL3579477 | 0.74 | MCHR1 (0.37) | C5AR1NLRP3CHRNA7 | |
| SCHEMBL3574217 | 0.73 | MCHR1 (0.37) | C5AR1NLRP3CHRNA7 | |
| SCHEMBL3577424 | 0.73 | NLRP3 (0.39) | C5AR1NLRP3PPARGPPARACHRNA7 | |
| SCHEMBL1397699 | 0.72 | C5AR1 (0.31) | C5AR1 | |
| SCHEMBL20768058 | 0.70 | UTS2R (0.33) | C5AR1PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007726-B1 | BENZAMIDE AND HETEROARENE DERIVATIVES AS CETP INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-03-02 | — | — | EP | disclosed |
| US-7674815-B2 | Heteroaryl and benzyl amide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-20070185113-A1 | Heteroaryl and benzyl amide compounds | HOFFMANN-LA ROCHE INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185113-A1 | Heteroaryl and benzyl amide compounds | CYP2C19, CYP2C9, CYP3A43 | C5AR1 2382/4885NLRP3 1203/4885PPARG 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.